Omeros Reports Strong Preliminary Cash Position of $171.5M for FY2025
OMER has more than doubled off its 52-week low of $2.95.
Summary
Omeros Corporation announced a preliminary cash and short-term investments balance of $171.5 million for fiscal year 2025, indicating strong liquidity and an extended operational runway.
Key Events · Financing and Capital Events · OMER
-
Preliminary Cash Balance Reported
Omeros Corporation reported approximately $171.5 million in cash and short-term investments as of December 31, 2025.
-
Strong Liquidity for Operations
This unaudited figure provides significant capital for the company's ongoing operations and research and development efforts.
-
Mitigates Near-Term Financing Risk
The substantial cash position enhances financial stability and reduces immediate concerns regarding capital requirements.
Analysis · OMER · Life Sciences
Omeros Corporation disclosed a robust preliminary cash and short-term investments balance of $171.5 million as of December 31, 2025. This significant liquidity provides a substantial operational runway, which is crucial for a life sciences company funding ongoing research and development. The strong cash position mitigates near-term financing risks and supports the company's strategic initiatives, offering investors confidence in its financial stability.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OMER was trading at $13.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $999M. The 52-week trading range was $2.95 to $17.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.